Peer-influenced content. Sources you trust. No registration required. This is HCN.

MDLinxSwabbing C-section Babies with Vaginal Fluid Improves Immunity

C-Section Delivery’s Impact on Infant Immunity: Microbiome Alterations and Vaccine Response

Recent research highlights the potential immunological consequences of cesarean section deliveries on newborns. Studies indicate that C-section babies, who miss exposure to the birthing parent’s vaginal microbiome, may experience altered immune development. This can affect their response to vaccinations, particularly the measles vaccine, and potentially increase their risk of certain health conditions. However, emerging interventions show promise in mitigating these effects.

Key Points:

  • C-section deliveries deprive newborns of exposure to crucial gut microbes present in the birthing parent’s vaginal microbiome.
  • A study published in Nature Microbiology found that the first dose of the measles vaccine is 2.56 times more likely to be ineffective in C-section babies compared to vaginally delivered infants.
  • Primary vaccine failure occurred in 12% of C-section babies versus 5% of vaginally delivered babies.
  • The second dose of the measles vaccine induced robust immunity in C-section babies, emphasizing the importance of follow-up vaccinations.
  • Lack of exposure to the maternal microbiome during birth may impact the postnatal development of the immune system.
  • Epidemiological data suggests a higher incidence of atopic diseases in infants born via C-section.
  • Delayed onset of lactation in C-section deliveries may further impact the establishment of a physiological intestinal flora.
  • A randomized controlled trial evaluated the effect of vaginal microbiota transfer on C-section newborns.
  • Vaginal microbiota transfer accelerated gut microbiota maturation and regulated certain fecal metabolites within 42 days after birth.
  • The study concluded that vaginal microbiota transfer is likely safe and may partially normalize the fecal microbiome in C-section infants.
  • Adverse events did not differ between the vaginal microbiota transfer group and the control group.

Globally, C-section use has increased by 3.7% each year between 2000-2015 — rising from 12% of live births (16 million of 131.9 million) in 2000, to 21% of live births (29.7 million of 140.6 million) in 2015. (Science Daily)

More on Neonatology

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form